Johnson & Johnson (JNJ) Q3 2026 Earnings: $5.5B Ovarian Talc Settlement

Johnson & Johnson (JNJ) reported third-quarter fiscal 2026 earnings on October 13, 2026, through an 8-K earnings release and an earnings call. Prescription drug growth accelerated, but the ovarian talc settlement and a MedTech slowdown weakened the earlier view of the company [1][2]. Earlier research focused on four questions: whether new prescription drugs could outrun the loss of exclusivity on STELARA, whether MedTech would reaccelerate in the second half, whether the roughly $3.4 billion talc reserve was enough, and whether free cash flow could fund the dividend, acquisitions and the orthopaedics separation at the same time. This quarter, prescription drug growth outran the erosion, but profit did not keep pace; MedTech slowed to 2.5%; and the company agreed to settle ovarian talc litigation for $5.5 billion and recorded the full amount [1][2]. Cash stayed on plan, with nine-month free cash flow of about $15.1 billion and net debt flat at about $28 billion [1][2].

Johnson & Johnson is a healthcare company with two segments, prescription medicines (Innovative Medicine) and medical technology (MedTech) [3]. In fiscal 2025, Innovative Medicine supplied 64.1% of sales and most of segment profit, while MedTech earned a much lower margin [3]. Litigation costs such as talc are not charged to either segment and affect only consolidated profit and cash [3].

Change one: a $5.5 billion ovarian talc settlement

The company announced in July an agreement to resolve ovarian talc litigation for $5.5 billion and recorded the full amount in the third quarter [2]. The present value of the talc reserve was about $3.4 billion at the end of fiscal 2025, so the new charge shows the earlier reserve did not cover the ovarian claims [3]. Litigation-related pre-tax special items were $5,519 million this quarter, compared with $15 million a year earlier [4]. The settlement and costs for the Firefly Bio and SAIL transactions totaled about $7 billion and reduced third-quarter GAAP net earnings from $5,152 million a year earlier to $210 million [1][2].

The settlement is not yet effective, and no cash has been paid. The agreement requires express participation from at least 95% of the remaining ovarian claims, and management said participation is trending toward that threshold [2]. The reserve balance after the settlement and the payment schedule have not been disclosed. The company kept its full-year free cash flow guidance of about $21 billion but did not say whether that guidance includes the payment [2].

Change two: prescription drug growth accelerated, but profit did not follow

Innovative Medicine sales were $16,757 million in the third quarter, up 7.9% excluding currency, faster than 6.8% in the second quarter [1][5]. STELARA sales fell 54.0% year over year, and its drag on segment growth narrowed from about 760 basis points to about 690 basis points [1][4][5]. TREMFYA grew 68.2%, adding $972 million, more than the $854 million that STELARA lost [4]. Icotide, a new oral psoriasis drug, has passed 20,000 cumulative U.S. patients, but its sales are not yet disclosed separately [2]. The company narrowed its full-year operational sales growth guidance from 6.5%–7.1% to 6.7%–7.1% [1].

Profit conversion lagged sales growth. On management's adjusted basis, the segment pre-tax margin fell from 44.3% a year earlier to 35.4%, which management attributed to about $1 billion of acquired in-process research and development expense for Firefly Bio, SAIL transaction costs and unfavorable product mix [2]. Adding back the Firefly expense gives a margin of about 41%, still below the prior year. Management estimates the two deals will reduce adjusted earnings per share by $0.64 in 2026 and by $1.36 in 2027 [2].

Change three: MedTech did not reaccelerate

MedTech grew 2.5% in the third quarter, slower than 3.6% in the second quarter, and management acknowledged the result was below the expectations it had previously given investors [1][2][5]. U.S. sales grew 4.8%, while sales outside the U.S. grew only 0.1% [2]. Surgery fell 1.0%, which management attributed to volume-based procurement in China, the surgery transformation program and the effect of the Middle East conflict on tenders; Abiomed fell 1.5% and has not returned to growth [2][4]. The segment's adjusted margin rose from 21.0% to 22.9%, mainly from tariff recoveries, which have limited staying power [2]. Management expects surgery to return to growth in the fourth quarter but did not quantify the individual headwinds [2].

Conclusion

This quarter's growth came mainly from prescription drugs, while profit and cash face new pressure. Prescription drug growth comes from prescription volume and share gains and should be relatively durable, but the fourth quarter includes a 53rd week that will inflate year-over-year growth, and deal dilution will continue into 2027 [2]. The MedTech recovery, the settlement taking effect and being paid, and full-year free cash flow all remain to be confirmed. The next evidence will come from the reserve balance and payment terms in the quarterly report, whether surgery and Abiomed return to growth in the fourth quarter, and whether the Innovative Medicine margin stops falling once deal costs are excluded.

Sources

[1] JNJ 8-K filed 2026-10-13 · Q3 2026 results release (Exhibit 99.1) — Johnson & Johnson Form 8-K earnings release, 2026-10-13, https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/a2026q3exhibit991.htm

[2] JNJ Q3 2026 earnings call 2026-10-13 — earnings call, 2026-10-13, https://www.investor.jnj.com/events-and-presentations/default.aspx

[3] JNJ FY2025 10-K filed 2026-02-11 — Johnson & Johnson Form 10-K, 2026-02-11, https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.htm

[4] JNJ 8-K filed 2026-10-13 · Q3 2026 supplementary sales data (Exhibit 99.2) — Johnson & Johnson Form 8-K supplementary sales data, 2026-10-13, https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/a2026q3exhibit992.htm

[5] JNJ Q2 2026 earnings call 2026-07-15 — earnings call, 2026-07-15, https://www.investor.jnj.com/events-and-presentations/default.aspx